Novel mechanisms of brequinar sodium immunosuppression on T cell activation

Transplantation

Volumn 58, Issue 8, 1994, Pages 920-926

  Forrest, Terry L ^a,b   Ware, Russell E ^a,b   Howard, Thad ^a,b   Jaffee, Bruce D ^a,b   Denning, Stephen M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREQUINAR; CYCLOSPORIN; DIHYDROOROTASE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE;

ARTICLE; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; T LYMPHOCYTE ACTIVATION;

BIPHENYL COMPOUNDS; DEPRESSION, CHEMICAL; DNA; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 0028004196     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199410270-00011     Document Type: Article

References (31)

1. Makowka L, Chapman F, Cramer DV. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc 1993; 25(suppl 2): 2.
2. Cramer DV, Chapman F, Makowka L. Prevention of vascular ized allograft and xenograft rejection in rodents by brequinar sodium. Transplant Proc 1993; 25(suppl 2): 23.
3. Simon P, Townsend RM, Harris RR, Jones EA, Jaffee BD. Bre quinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro. Transplant Proc 1993; 25(suppl 2): 77.
4. Cramer DV, Chapman FA, Jaffee BD, et al. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 1992; 53: 303.
5. Cramer DV, Chapman FA, Jaffee BD, et al. The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium. Transplantation 1992; 54: 403.
6. Cosenza CA, Cramer DV, Eiras-Hreha G, Cajulis E, Wang HK, Makowka L. Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection. Transplant Proc 1993; 25(suppl 2): 57.
7. Stepkowski SM, Kahan BD. Synergistic activity of the triple combination: cyclosporine, rapamycin and brequinar sodium. Transplant Proc 1993; 25(suppl 2): 29.
8. Cosenza CA, Tuso PJ, Chapman et al. Prolonged xenograft sur vival following combination therapy with brequinar sodium and cyclosporine. Transplant Proc 1993; 25(suppl 2): 59.
9. Martin PJ, Longton G, Ledbetter JA, et al. Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol 1983; 131: 180.
10. Bernard A, Knowles RW, Naito K, et al. A unique epitope on the CD2 molecule defined by the monoclonal antibody 9-1: epitope-specific modulation of the E-rosette receptor and effects on T cell functions. Hum Immunol 1986; 17: 388.
11. Yang SY, Chouaib S, DuPont B. A common pathway for T lym phocyte activation involving both the CD3-TÌ complex and CD2 sheep erythrocyte receptor determinants. J Immunol 1986; 137: 1097.
12. Haynes BF, Harden EA, Telen MJ, et al. Differentiation of hu man T lymphocytes: I. Acquisition of a novel human cell surface protein (p80) during normal intrathymic T cell maturation. J Immunol 1983; 131: 1195.
13. Haynes BF. Summary of T cell studies performed during the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Beinstein ID, eds. Leukocyte typing II. New York: Springer, 1986: 3.
14. Van Wauwe JP, De Mey JR, Goosens JG. OKT3: a monoclonal anti-human lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708.
15. Denning SM, Tuck DT, Singer KH, Haynes BF. Human thymic epithelial cells function as accessory cells for autologous mature thymocyte activation. J Immunol 1987; 138: 680.
16. Watson J. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med 1979; 150: 1510.
17. Wang A, Lu SD, Mark DF. Site specific mitogenesis of the hu man interleukin-2 gene: structure-function analysis of the cysteine residues. Science 1984; 224: 1431.
18. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412.
19. Haynes BF, Metzgar RS, Minna JD, Bunn PA. Phenotypic char acterization of cutaneous T-cell lymphoma. N Engl J Med 1991; 304: 1319.
20. Fried J, Perez AG, Clarkson BD. Flow cytotluorometric analysis of cell cycle distributions using propidium iodide. J Cell Biol 1976; 71: 172.
21. − thymic T cell precursors differentiate in vitro into T cell receptor δ-bearing cells. J Immunol 1989; 142: 2988.
22. Ware RE, Hart MK, Haynes BF. Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux. J Immunol 1991; 147: 2787.
23. Clark SC, Arya SK, Wong-Staal F, et al. Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells. Proc Natl Acad Sci USA 1984; 81: 2543.
24. Leonard WJ, Depper JM, Crabtree GR, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 1984; 311: 626.
25. Van Lier RAW, Brouwer M, Aarden LA. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol 1988; 18: 167.
26. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against CD44, p80, lymphocyte homing receptor augment human peripheral blood T cell activation. J Immunol 1990; 144: 7.
27. Lemster B, Woo J, Strednak J, et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid or brequinar sodium. Transplant Proc 1992; 24: 2845.
28. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell 1991; 66: 807.
29. O'keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357: 692.
30. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169.
31. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987; 7: 4472.